Powered by Ranger® Technology, the LightBench® Detect is optimised for use with EDTA blood collection tubes (BCTs) in Yourgene Health’s clinical NIPT workflows. The LightBench® Detect reduces overall workflow costs and improves patient outcomes.
The LightBench® Detect, powered by Ranger® Technology, is Yourgene’s clinical-grade size selection instrument, and offers industry-leading scalability and precision for the DNA size selection process. We’ve worked with our clinical laboratory partners to design an instrument that specifically addresses the needs of liquid biopsy providers, in particular NIPT.
Since cfDNA fragments of fetal origin are typically <150 bp in length, size selection using the LightBench® Detect can enrich the fetal fraction in the maternal sample, which reduces the number of no-call results or screening failures, improving overall patient outcomes.
The LightBench® Detect also leverages patent-pending size-selection technology from Yourgene Health, making it the only instrument that enables laboratories to consider the use of EDTA blood collection tubes (BCTs) instead of Streck BCTs. This reduces the laboratory’s expense on blood collection tubes.
Enriching fetal fraction through automated size selection of fragment lengths provides more of the DNA fragments we are looking for. This improves outcomes for NIPT patients by reducing the cost of analysis, reducing false positives/negatives and reducing the number of no-call tests due to too low a fetal fraction for analysis. Providing patients with fast, safe and accurate screening results.
Like the other instruments in the range the LightBench® Detect can be integrated with automated robotics to provide a fully automated size selection and quality control workflow.
Band Pass
8 (SBS-Format)
A Ranger® Technology Applications: Size Selection for NIPT, Oncology and Gene Synthesis Applications
In this edition of YourExpert, Yourgene Health interviewed Matthew Nesbitt, one of the developers of Ranger® Technology to discuss how its unique size selection function is helping our collaborators in life sciences and synthetic biology, across various clinical and research applications.
Achieving cost savings in NIPT by enabling greater flexibility in blood collection tube choice
Non-invasive prenatal testing (NIPT) involves sequencing cell-free DNA (cfDNA) from maternal plasma to screen for fetal trisomy 21, 18, and 13, and in some instances other chromosomal abnormalities. Making NIPT routinely available has required the use of blood collection tubes (BCTs) that maintain the sample at ambient temperatures, whilst also retaining the integrity of the cell-free DNA (cfDNA) population. This allows for sample shipping without prior centrifugation and freezing, enabling efficient transport to centralised laboratory locations from sample collection clinics. Blood cells must be stabilised to prevent dilution of the fetal cfDNA portion with wild-type genomic DNA.
Videos
Introducing Ranger® Technology
View the full Your Comment articles below
Ranger® Revolution - LightBench® Detect is here! - 20 June 2022
Ranger® Revolution – LightBench® Detect is Here! The wait is over! Yourgene Health are proud to today reveal the Ranger® Revolution in the form of the LightBench® Detect; the latest addition to our Ranger® Technology portfolio. We’ve worked closely with our clinical laboratory partners to develop a size selection instrument that is optimised for improving the performance of liquid biopsy workflows, most notably non-invasive prenatal testing (NIPT). The LightBench® Detect addresses a pressing need for NIPT providers to be able to reduce no-call rates by optimising average fetal fraction. Additionally, by leveraging patent-pending size-selection technology from Yourgene Health, the LightBench® Detect is the only size-selection instrument that enables laboratories to consider the use of EDTA blood collection tubes (BCTs) instead of Streck BCTs. Ranger® Technology in NIPT – 3-in-1 Solution Ranger® Technology offers industry-leading scalability and precision for the DNA size selection process. The core size selection functionality is complemented by the ability to perform fragment length analysis and fluorescence assays for quality control purposes. Since cfDNA fragments of fetal origin are typically <150bp in length, size selection using Ranger® Technology can enrich for fetal fraction to reduce the number of no-call results or screening failures. Use of the technology in NIPT has already been demonstrated to secure an average recovery yield of over 70%. Unlike traditional electrophoretic size selection approaches, >97% reproducibility is possible, and ensures consistent enrichment of the fetal fraction. The existing LightBench® specifically addresses the needs of research applications, including metagenomics and sequence discovery. EDTA BCTs in NIPT Recent work presented by the Centre de recherche du CHU de Québec-Université Laval, demonstrated a patent-pending ability of Ranger® Technology to enable laboratories to consider the use of EDTA BCTs instead of Streck BCTs in their workflows (1). The group worked with Yourgene Health to compare fetal fraction in 61 samples collected from singleton pregnancies in Vancouver over a two month period. Each pregnancy had two 10mL peripheral blood samples taken; one in EDTA and one Streck. Samples from EDTA tubes with size selection had no failures, and an average fetal fraction of 13%; a significant increase compared to Streck tubes (7%). They concluded that the addition of this size-selection step is ‘a strategy that significantly increases fetal fraction and reduces the number of no-call results due to low fetal fraction…[this is] a cost-saving measure for the laboratory and benefits women’ (1). In doing so, they demonstrated that Ranger® Technology offers an alternative solution to the use of Streck BCTs for stabilising NIPT samples. Dr François Rousseau from the Université Laval presented this work at the Labroots 2022 Genetics Virtual Week event, and you can watch an on demand recording. Yourgene Health have now made this capability accessible to the market exclusively via the LightBench® Detect. Ranger® Technology is the only size-selection methodology capable of offering this flexibility in BCT choice. LightBench® Detect The LightBench® Detect is currently the only instrument in the Ranger® portfolio capable of leveraging the patent-pending EDTA size selection approach tested by the Laval group. Yourgene Health have conducted extensive analysis in collaboration with our clinical laboratory partners to understand both the potential clinical and economic benefits that could be achieved in adopting the LightBench® Detect. You can read the results of this analysis in our Your Expert article on cost savings here. Ranger® Roadmap At this time, the development will only be accessible to Yourgene’s non-IONA® Nx NIPT customers, including Sage™ 32plex, as the feature is not yet available on the QS250. The Yourgene® QS250 is optimised for use in Yourgene’s end-to-end NIPT workflow offerings. This decision is part of Yourgene’s recently announced commitment to a next-generation approach to delivery of NIPT testing solutions, with a focus on ‘Collaboration to Perform’. Working as a partnership, rather than the traditional laboratory/manufacturer relationship, represents a shared commitment to ensuring high-quality and performance-driven testing, ultimately delivering better outcomes for patients. For these reasons, we are first collaborating with a subset of IONA® Nx customers to collect robust validation data to support the proper utilisation of this development within the QS250 i.e. a CE-IVD environment. We anticipate these validation studies will be completed within 2022, at which time we will begin development within the IONA® workflow. Liquid Biopsy in the Clinic The LightBench® Detect is the optimal choice for laboratories looking to translate their oncology liquid biopsy workflows into routine clinical practice. You can find out more about how Ranger® Technology can help address the challenges of tumor specific variant profiling in cancer patients by watching this on demand webinar, featuring Kimberly Holden, Research Associate in Oncology Diagnostics Assay Development at Labcorp. Do you like the sound of being able to use EDTA tubes in your NIPT workflow whilst maximising fetal fraction? Read our latest Your Expert article ‘Achieving cost savings in NIPT by enabling greater flexibility in blood collection tube choice’, or get in touch at updates@yourgene-health.com If you’re a current IONA® Nx customer interested in becoming an early adopter and working with us on the QS20 validation study, please contact your local account manager, or by using the email updates@yourgene-health.com Reference: 2022. Improving fetal fraction in NIPT by size selection of samples collected in EDTA gel tubes [Poster]. ISPD (26th International Conference on Prenatal Diagnosis and Therapy), 20-22 June 2022, Stand 205. Ranger® Revolution – LightBench® Detect is here! – 20 June 2022
ISPD 2023 EDTA Poster P94
A study to demonstrate that prolonged storage of blood in EDTA tubes is compatible with NIPT when using size selection to enrich fetal fraction present.
Labroots Webinar
Watch the webinar ‘Improving Fetal Fraction of EDTA-Gel NIPS Samples Using Gel-Based Size-Selection’ discussing the LightBench® Detect EDTA capabilities, presented by Francois Rousseau et al at CHU de Québec - Université Laval, Canada, at the Labroots Genetics Week Virtual Event 2022.
Québec-Université Laval white paper
Current Customer Contact Form
New Enquiry Contact Form
For current customers and distributors seeking access to product information including IFU’s, Software Analysis Files, Safety Data Sheets and Supplementary Information please login here
If you require a login please email marketing@yourgenehealth.com
